Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

Giovanna Fico; Ulker Isayeva; Michele De Prisco; Vincenzo Oliva; Brisa Solè; Laura Montejo; Iria Grande; Nestor Arbelo; Marta Gomez-Ramiro; Luis Pintor; Bernardo Carpiniello; Mirko Manchia; Eduard Vieta; Andrea Murru

doi:10.1016/j.euroneuro.2022.10.004

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

Giovanna Fico, Ulker Isayeva, Michele De Prisco, Vincenzo Oliva, Brisa Solè, Laura Montejo, Iria Grande, Nestor Arbelo, Marta Gomez-Ramiro, Luis Pintor, Bernardo Carpiniello, Mirko Manchia, Eduard Vieta, Andrea Murru

Medicine

Résultat de recherche: Review article › examen par les pairs

19 Citations (Scopus)

Résumé

Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65–4.51) or mortality (RR=0.94; CI 0.81–1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02–0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76–4.85) and mortality (OR=1.53; CI 1.15–2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.

Langue d'origine	English
Pages (de-à)	30-44
Nombre de pages	15
Journal	European Neuropsychopharmacology
Volume	66
DOI	https://doi.org/10.1016/j.euroneuro.2022.10.004
Statut de publication	Published - janv. 2023

Note bibliographique

Funding Information:
IG thanks the support of the Spanish Ministry of Science and Innovation (MCIN) ( PI19/00954 ) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación y el Fondos Europeos de la Unión Europea (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM) ; and the the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement ( 2017 SGR 1365 ), CERCA Programme / Generalitat de Catalunya. EV thanks the support of the Spanish Ministry of Science and Innovation ( PI18/00805 , PI21/00787 ) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM) ; the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement ( 2017 SGR 1365 ), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357 . Thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease : Grant No 945151 ). AM has received a grant ( PI19/00672 ) from the Instituto de Salud Carlos III Subdirección General de Evaluación y Fomento de la investigación , Plan Nacional 2019-2022. The project that gave rise to these results received the support of a fellowship from "La Caixa" Foundation (ID 100010434 ). The fellowship code is LCF/BQ/DR21/11880019.

Funding Information:
IG thanks the support of the Spanish Ministry of Science and Innovation (MCIN) (PI19/00954) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación y el Fondos Europeos de la Unión Europea (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and the the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), CERCA Programme / Generalitat de Catalunya. EV thanks the support of the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease: Grant No 945151). AM has received a grant (PI19/00672) from the Instituto de Salud Carlos III Subdirección General de Evaluación y Fomento de la investigación, Plan Nacional 2019-2022. The project that gave rise to these results received the support of a fellowship from "La Caixa" Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880019.

Publisher Copyright:
© 2022 Elsevier B.V. and ECNP

ASJC Scopus Subject Areas

Pharmacology
Neurology
Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry
Pharmacology (medical)

PubMed: MeSH publication types

Journal Article
Review

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1016/j.euroneuro.2022.10.004

Autres fichiers et liens

Citer

@article{6715f17b5ed54168b54e402ce51a5781,

title = "Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis",

abstract = "Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65–4.51) or mortality (RR=0.94; CI 0.81–1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02–0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76–4.85) and mortality (OR=1.53; CI 1.15–2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.",

author = "Giovanna Fico and Ulker Isayeva and {De Prisco}, Michele and Vincenzo Oliva and Brisa Sol{\`e} and Laura Montejo and Iria Grande and Nestor Arbelo and Marta Gomez-Ramiro and Luis Pintor and Bernardo Carpiniello and Mirko Manchia and Eduard Vieta and Andrea Murru",

note = "Funding Information: IG thanks the support of the Spanish Ministry of Science and Innovation (MCIN) ( PI19/00954 ) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirecci{\'o}n General de Evaluaci{\'o}n y el Fondos Europeos de la Uni{\'o}n Europea (FEDER, FSE, Next Generation EU/Plan de Recuperaci{\'o}n Transformaci{\'o}n y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM) ; and the the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement ( 2017 SGR 1365 ), CERCA Programme / Generalitat de Catalunya. EV thanks the support of the Spanish Ministry of Science and Innovation ( PI18/00805 , PI21/00787 ) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM) ; the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement ( 2017 SGR 1365 ), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357 . Thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease : Grant No 945151 ). AM has received a grant ( PI19/00672 ) from the Instituto de Salud Carlos III Subdirecci{\'o}n General de Evaluaci{\'o}n y Fomento de la investigaci{\'o}n , Plan Nacional 2019-2022. The project that gave rise to these results received the support of a fellowship from {"}La Caixa{"} Foundation (ID 100010434 ). The fellowship code is LCF/BQ/DR21/11880019. Funding Information: IG thanks the support of the Spanish Ministry of Science and Innovation (MCIN) (PI19/00954) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirecci{\'o}n General de Evaluaci{\'o}n y el Fondos Europeos de la Uni{\'o}n Europea (FEDER, FSE, Next Generation EU/Plan de Recuperaci{\'o}n Transformaci{\'o}n y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and the the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), CERCA Programme / Generalitat de Catalunya. EV thanks the support of the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease: Grant No 945151). AM has received a grant (PI19/00672) from the Instituto de Salud Carlos III Subdirecci{\'o}n General de Evaluaci{\'o}n y Fomento de la investigaci{\'o}n, Plan Nacional 2019-2022. The project that gave rise to these results received the support of a fellowship from {"}La Caixa{"} Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880019. Publisher Copyright: {\textcopyright} 2022 Elsevier B.V. and ECNP",

year = "2023",

month = jan,

doi = "10.1016/j.euroneuro.2022.10.004",

language = "English",

volume = "66",

pages = "30--44",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Psychotropic drug repurposing for COVID-19

T2 - A Systematic Review and Meta-Analysis

AU - Fico, Giovanna

AU - Isayeva, Ulker

AU - De Prisco, Michele

AU - Oliva, Vincenzo

AU - Solè, Brisa

AU - Montejo, Laura

AU - Grande, Iria

AU - Arbelo, Nestor

AU - Gomez-Ramiro, Marta

AU - Pintor, Luis

AU - Carpiniello, Bernardo

AU - Manchia, Mirko

AU - Vieta, Eduard

AU - Murru, Andrea

N1 - Funding Information: IG thanks the support of the Spanish Ministry of Science and Innovation (MCIN) ( PI19/00954 ) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación y el Fondos Europeos de la Unión Europea (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM) ; and the the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement ( 2017 SGR 1365 ), CERCA Programme / Generalitat de Catalunya. EV thanks the support of the Spanish Ministry of Science and Innovation ( PI18/00805 , PI21/00787 ) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM) ; the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement ( 2017 SGR 1365 ), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357 . Thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease : Grant No 945151 ). AM has received a grant ( PI19/00672 ) from the Instituto de Salud Carlos III Subdirección General de Evaluación y Fomento de la investigación , Plan Nacional 2019-2022. The project that gave rise to these results received the support of a fellowship from "La Caixa" Foundation (ID 100010434 ). The fellowship code is LCF/BQ/DR21/11880019. Funding Information: IG thanks the support of the Spanish Ministry of Science and Innovation (MCIN) (PI19/00954) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación y el Fondos Europeos de la Unión Europea (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and the the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), CERCA Programme / Generalitat de Catalunya. EV thanks the support of the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease: Grant No 945151). AM has received a grant (PI19/00672) from the Instituto de Salud Carlos III Subdirección General de Evaluación y Fomento de la investigación, Plan Nacional 2019-2022. The project that gave rise to these results received the support of a fellowship from "La Caixa" Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880019. Publisher Copyright: © 2022 Elsevier B.V. and ECNP

PY - 2023/1

Y1 - 2023/1

N2 - Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65–4.51) or mortality (RR=0.94; CI 0.81–1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02–0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76–4.85) and mortality (OR=1.53; CI 1.15–2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.

AB - Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65–4.51) or mortality (RR=0.94; CI 0.81–1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02–0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76–4.85) and mortality (OR=1.53; CI 1.15–2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.

UR - http://www.scopus.com/inward/record.url?scp=85142210275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142210275&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2022.10.004

DO - 10.1016/j.euroneuro.2022.10.004

M3 - Review article

C2 - 36399837

AN - SCOPUS:85142210275

SN - 0924-977X

VL - 66

SP - 30

EP - 44

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer